Respiratory Disease Testing Market Size & Trends 2033

The Respiratory Disease Testing Market, estimated at USD 3,642.6 Mn in 2026, is expected to exhibit a CAGR of 4.2% and reach USD 4,858.3 Mn by 2033.

The industry is witnessing significant growth driven by rising demand for advanced, reliable, and cost-effective medical devices across diagnostic, therapeutic, and monitoring applications. Rapid advancements in device design, digital health integration, and adoption of minimally invasive technologies are reshaping the competitive landscape. Furthermore, supportive regulatory frameworks, increasing healthcare investments, and the growing focus on patient-centric care are expected to create new growth avenues for market players.

Major players in the market are focused on inorganic strategies such as funding to enhance its market share. For instance, in May 2025, CARB-X Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator, a nonprofit partnership focused on supporting antibacterial research, announced it is awarding Microbion Corporation is a clinical-stage pharmaceutical company developing a novel class of compounds for the diagnosis of difficult-to-treat infections in Bozeman, USA, US$ 6.1 million plus up to $5.4 million more if certain project milestones are met, to develop its anti-infective drug pravibismane for the treatment of cystic fibrosis (CF)-related pulmonary infections.

Global Respiratory Disease Testing Market – Driver

Persistent Circulation of Respiratory Infections

Continued circulation of influenza, RSV, and other respiratory pathogens is increasing routine diagnostic and surveillance testing. In July 2026, WHO reported influenza positivity above 10% in several countries and RSV positivity exceeding 30% in selected countries in Eastern Africa and Southern Asia. Recurring seasonal outbreaks support demand for antigen, molecular, serological, and multiplex respiratory tests. (Source: WHO)

Expansion of Public-Health Surveillance Infrastructure

Government investment in laboratory networks, genomic sequencing, and integrated respiratory-virus surveillance is supporting test procurement and laboratory expansion. In April 2026, WHO reported that National Influenza Centres in its European Region had increased from 41 to 47, while surveillance platforms increasingly incorporated influenza. (Source: WHO)

Global Respiratory Disease Testing Market – Opportunity

Expansion of Near-Point-of-Care Molecular Testing

Portable molecular testing systems represent a major opportunity, particularly in primary-care facilities, community clinics, mobile laboratories, and rural healthcare centres. On March 24, 2026, the World Health Organization recommended new near-point-of-care tuberculosis tests and tongue-swab-based testing methods. WHO stated that these portable, easy-to-use tests can be offered at less than half the cost of many existing molecular diagnostic systems. This creates opportunities for compact analysers, test cartridges, swab kits and decentralized diagnostic services. (Source: WHO)

Diagnostic Expansion Across High-Burden Emerging Markets

Countries with high tuberculosis and respiratory infection burdens offer substantial opportunities for diagnostic manufacturers, distributors and laboratory-service providers. In June 2026, the Global Fund announced that 13 countries were preparing to introduce a first-in-class near-point-of-care molecular TB test through its Early Adopter initiative. The programme brings testing closer to communities and healthcare facilities with limited laboratory infrastructure. Manufacturers can benefit through public procurement, local production, distribution partnerships, instrument-placement models and long-term reagent supply contracts. (Source: Global Funds)

Global Respiratory Disease Testing Market – Trends

Expansion of Near-Point-of-Care Molecular Testing

Respiratory testing is shifting from centralized laboratories toward clinics, primary healthcare facilities, and community settings. Compact molecular systems provide laboratory-quality results closer to patients. In March 2026, WHO issued its first recommendations for near-point-of-care molecular tuberculosis tests, along with tongue-swab sampling and sputum pooling, to simplify collection, lower testing costs, and expand diagnostic access.

Introduction of Compact, Symptom-Based Syndromic Panels

Manufacturers are developing smaller and more targeted panels for outpatient and near-patient settings. These tests allow clinicians to select either broad or limited pathogen menus based on symptoms, clinical needs, and testing budgets. In March 2026, bioMérieux received European CE-IVDR marking for its BIOFIRE SPOTFIRE Respiratory/Sore Throat Plus Panel and Mini Panel, both designed for compact multiplex PCR testing.

Integration of Artificial Intelligence into Lung-Disease Detection

AI-enabled diagnostic software is increasingly being used to identify pulmonary nodules, assess malignancy risk, and prioritize suspicious imaging examinations. The trend is strengthening the imaging component of respiratory disease testing. In January 2026, the FDA cleared RevealAI-Lung for lung-nodule risk assessment, while eyonis LCS, an AI-based lung cancer screening solution, received FDA clearance on February 6, 2026.

Increasing Automation and Higher Laboratory Throughput

Automated cartridge loading, sample processing, result interpretation, and waste management are reducing laboratory workload and improving testing capacity. In March 2026, QIAGEN expanded its QIAstat-Dx Rise platform in the U.S. The system supports respiratory and other syndromic panels, offers automated cartridge handling and can process up to 160 tests per day, supporting high-volume diagnostic laboratories.

Integrated Surveillance of Multiple Respiratory Pathogens

Public-health agencies are moving from disease-specific surveillance toward combined monitoring of influenza, SARS-CoV-2, RSV, and other respiratory viruses. This approach increases demand for standardized testing, multiplex reagents, sequencing, and connected laboratory platforms. In July 2026, WHO continued encouraging countries to use multiplex influenza and SARS-CoV-2 kits and report laboratory data through regional platforms and RespiMart.

Greater Focus on Testing Capacity and Supply-Chain Resilience

Diagnostic companies are increasing regional manufacturing capacity to ensure reliable supplies of PCR cartridges and syndromic testing panels during seasonal outbreaks. In May 2026, bioMérieux announced an investment of more than €250 million to establish a French manufacturing facility dedicated to BIOFIRE PCR tests. The investment demonstrates rising long-term demand for rapid syndromic diagnostics in Europe.

Adoption of Easier and Less-Invasive Sample-Collection Methods

The market is moving toward samples that are easier to collect than conventional sputum or deep nasopharyngeal specimens. Tongue swabs, anterior nasal swabs, and self-collected samples can expand testing among children, older adults, and underserved populations. In May 2026, WHO and the Stop TB Partnership published a toolkit supporting near-point-of-care nucleic-acid tests and swab-based TB testing in primary-care and community settings.

Global Respiratory Disease Testing Market: Key Developments

In July 2026, NSG Biolabs, co-working BSL-2 laboratory launched The Impulse initiative under NSG Bio Tomorrow, with support from Chiesi Group, to advance biotechnology innovation in respiratory and neonatal care. The selected startup will receive one year of NSG Bio membership, a dedicated laboratory bench, research infrastructure, shared workspaces, and access to industry networks. The program targets innovations including cell and gene therapies, regenerative engineering, lung-targeted delivery, preventive approaches, and small-molecule development platforms.
In March 2026, Roche launched the cobas eplex Respiratory Pathogen Panel 3 in CE-marked markets. The molecular diagnostic test simultaneously differentiates up to 25 viral and bacterial targets, including influenza A and B, RSV, SARS-CoV-2, Bordetella parapertussis, and Chlamydia pneumoniae. Requiring less than one minute of hands-on time, the flexible system enables laboratories to customize five panels, supporting faster treatment decisions, infection control, and reduced unnecessary antibiotic use in hospitals.
On March 15, 2025, Cepheid, a molecular diagnostics company, unveiled its first manufacturing unit in India at Mahadeva Kodigehalli, Bengaluru. The 77,000 square-foot facility will manufacture the company’s industry Xpert Staphylococcus Aureus testing cartridges for India and other countries.
In April 2025, Samsung digital radiography and ultrasound systems, introduced the GM85 Fit, a new configuration of the premium AccE GM85; a digital radiography device featuring a user-centric design that aids in efficient and effective patient care. The GM85 Fit recently received 510(k) clearance from the U.S. Food and Drug Administration for commercial use in the USA.
In June 26, 2025, Savara Inc., a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced that enrollment has been completed for the pivotal Phase 3 IMPALA-2 trial. A total of 164 patients were randomized. Target enrollment for the trial was 160 patients. The Company expects to report top line results by the end of 2Q 2025. IMPALA-2 is a global, 48-week, placebo-controlled clinical trial evaluating molgramostim, a novel inhaled biologic, for the Diagnosis of aPAP (Automatic Positive Airway Pressure), a rare lung disease with no approved pharmacological treatments.

To know the latest trends and insights prevalent in this market, click the link below:

https://www.coherentmarketinsights.com/market-insight/respiratory-disease-testing-market-4030

Key Takeaways of the Global Respiratory Disease Testing Market

The global respiratory disease testing market is expected to exhibit a CAGR of 4.2% during the forecast period. Market players are involved in deploying strategic initiatives, which include product launched and expansion of distribution networks, among others. For instance, in November 2025, Cipla Limited, an multinational pharmaceutical company in India, has launched pirofy Device in India to Help Test Lung Function its wireless, portable device capable of performing lung function tests outdoors and in remote areas
Among Test Type, the imaging tests is anticipated to hold a significant share in the respiratory disease testing market during the forecast period. This is due to its wide range of advantages, such as the compact size of the device, higher accuracy, longer life. For Instance, On March 06, 2025 Vitalograph, a developer and producer of respiratory diagnostic devices, has launched its VitaloPFT Pulmonary Function Testing Series, aimed for use in secondary care.
Among region, North America is expected to be the dominant region in the global respiratory disease testing market, owing to the increase asthmatic patients. For instance, the data provided by Statistics Canada in September 2025 for health characteristics and annual estimates for asthma an increase in 2025 from the previous years. The number of people affected by asthma increased to 2,802,700 in 2025. This burden of asthma in the country is expected to increase demand for early diagnosis of the disease. This is expected to drive the studied market growth in Canada, fueling the overall market growth in the region.
Major players operating in the respiratory disease testing market are CareFusion Corporation, Carestream Health, Inc., COSMED, Futuremed America, Inc., GE Healthcare, MGC Diagnostics Corporation, ndd Medical Technologies, Inc., Nihon Kohden Corporation, Perkin Elmer, Inc., FUJIFILM Healthcare Corporation, Philips Healthcare,Roche Healthcare, Beckton Dickinson and Company, Koninklijke Philips N.V. ResMed Inc., Medtronic, Abbott Diagnostics, and Quest Diagnostics.